RBC Bioscience Corporation (TPEX:6848)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
19.15
-0.45 (-2.30%)
At close: Apr 24, 2026
Market Cap248.49M -2.3%
Revenue (ttm)219.71M +3.7%
Net Income23.54M +13.5%
EPS1.64 +13.6%
Shares Out12.98M
PE Ratio11.68
Forward PEn/a
Dividend0.30 (1.57%)
Ex-Dividend DateOct 2, 2025
Volume49,661
Average Volume64,313
Open19.55
Previous Close19.60
Day's Range19.10 - 19.60
52-Week Range14.30 - 20.75
Beta0.20
RSI66.63
Earnings DateApr 28, 2026

About RBC Bioscience

RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis Taiwan. It offers MagCore Plus II Automated Nucleic Acid Extractor, a robotic bench-top workstation for nucleic acid purification; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore® EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1995
Employees 52
Stock Exchange Taipei Exchange
Ticker Symbol 6848
Full Company Profile

Financial Performance

In 2024, RBC Bioscience's revenue was 205.25 million, an increase of 19.01% compared to the previous year's 172.47 million. Earnings were 21.57 million, an increase of 235.40%.

Financial Statements